Lovey; Raymond G.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Lovey; Raymond G..The latest application filed is for "novel peptides as ns3-serine protease inhibitors of hepatitis c virus".

Company Profile

0.24.15

Lovey; Raymond G. - West Caldwell NJ
Lovey; Raymond G. - Miami FL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Peptides as NS3-serine protease inhibitors of hepatitis C virus Grant RE43,298 - Saksena , et al. April 3, 2	2012-04-03
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease Grant 8,067,379 - Bennett , et al. November 29, 2	2011-11-29
Novel Peptides As Ns3-serine Protease Inhibitors Of Hepatitis C Virus App 20110117057 - Saksena; Anil K. ; et al.	2011-05-19
Peptides as NS3-serine protease inhibitors of hepatitis C virus Grant 7,595,299 - Saksena , et al. September 29, 2	2009-09-29
Peptides as NS3-serine protease inhibitors of hepatitis C virus Grant 7,244,721 - Saksena , et al. July 17, 2	2007-07-17
Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease App 20070042968 - Bennett; Frank ; et al.	2007-02-22
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus App 20070032433 - Saksena; Anil K. ; et al.	2007-02-08
Peptides as NS3-serine protease inhibitors of hepatitis C virus Grant 7,169,760 - Saksena , et al. January 30, 2	2007-01-30
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection Grant 7,115,578 - Ganguly , et al. October 3, 2	2006-10-03
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus App 20060205672 - Saksena; Anil K. ; et al.	2006-09-14
Peptides as NS3-serine protease inhibitors of hepatitis C virus Grant 7,012,066 - Saksena , et al. March 14, 2	2006-03-14
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus App 20050176648 - Saksena, Anil K. ; et al.	2005-08-11
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection Grant 6,924,270 - Ganguly , et al. August 2, 2	2005-08-02
Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus Grant 6,911,428 - Zhu , et al. June 28, 2	2005-06-28
Compounds as NS3-serine protease inhibitors of hepatitis C virus Grant 6,894,072 - Arasappan , et al. May 17, 2	2005-05-17
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus App 20050059606 - Saksena, Anil K. ; et al.	2005-03-17
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection App 20050004053 - Ganguly, Ashit K. ; et al.	2005-01-06
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus App 20040254117 - Saksena, Anil K. ; et al.	2004-12-16
Peptides as NS3-serine protease inhibitors of hepatitis C virus Grant 6,800,434 - Saksena , et al. October 5, 2	2004-10-05
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection Grant 6,673,775 - Ganguly , et al. January 6, 2	2004-01-06
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus App 20030216325 - Saksena, Anil K. ; et al.	2003-11-20
Novel compounds as NS3-serine protease inhibitors of hepatitis C virus App 20030207861 - Arasappan, Ashok ; et al.	2003-11-06
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus App 20030036501 - Saksena, Anil K. ; et al.	2003-02-20
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection App 20030004119 - Ganguly, Ashit K. ; et al.	2003-01-02
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus App 20020160962 - Saksena, Anil K. ; et al.	2002-10-31
Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus App 20020147139 - Zhu, Zhaoning ; et al.	2002-10-10
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection Grant 6,403,564 - Ganguly , et al. June 11, 2	2002-06-11
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection App 20020055473 - Ganguly, Ashit K. ; et al.	2002-05-09
5'-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon Grant 6,277,830 - Ganguly , et al. August 21, 2	2001-08-21
Soluble azole antifungal salt Grant 5,883,097 - Lovey , et al. March 16, 1	1999-03-16
Tetrahydrofuran antifungals Grant 5,714,490 - Saksena , et al. February 3, 1	1998-02-03
Tetrahydrofuran antifungals Grant 5,710,154 - Saksena , et al. January 20, 1	1998-01-20
Tetrahydrofuran antifungals Grant 5,693,626 - Saksena , et al. December 2, 1	1997-12-02
Tetrahydrofuran antifungals Grant 5,661,151 - Saksena , et al. August 26, 1	1997-08-26
Process for preparing intermediates for the synthesis of antifungal agents Grant 5,403,937 - Saksena , et al. April 4, 1	1995-04-04
1-Aryl-1-(1H-azol-1-ylalkyl)-1,3-dihydroisobenzofurans, related derivatives and pharmaceutical compositions thereof useful as antifungals Grant 4,877,801 - Lovey , et al. October 31, 1	1989-10-31
Imidazo[1,2-a]pyrazines Grant 4,507,294 - Bristol , et al. March 26, 1	1985-03-26
1,2,4-Triazolo[4,3-a]pyridines Grant 4,358,453 - Bristol , et al. November 9, 1	1982-11-09
1,3,4-Triazolo[1,5-a]pyridines Grant 4,358,454 - Bristol , et al. November 9, 1	1982-11-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.